<DOC>
	<DOCNO>NCT02861690</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerance efficacy Liposomal Paclitaxel With Nedaplatin First-line patient Advanced Recurrent Esophageal Carcinoma</brief_summary>
	<brief_title>Liposomal Paclitaxel Combined Nedaplatin Treatment Advanced Recurrent Esophageal Carcinoma</brief_title>
	<detailed_description>The purpose study evaluate safety , tolerance efficacy Liposomal Paclitaxel With Nedaplatin First-line patient Advanced Recurrent Esophageal Carcinoma.Patients receive Liposomal Paclitaxel 175mg/m2 Nedaplatin 80mg/m2 every 21 day presence progressive disease unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1. histological confirm advanced metastatic recurrent esophageal cancer 2. age 18 80 year 3 . ECOG performance status 0 2 4. life expectancy ≥ 12 week 5. evaluable disease Response Evaluation Criteria Solid Tumors ( RECIST ) 6. least one prior chemotherapy regimen 7. adequate bone marrow function define absolute neutrophil count equal 2000/mm3 8. platelet count equal 100,000/mm3 hemoglobin equal 8 g/dL 9. adequate renal function define creatinine le equal 1.25 × upper limit normal ( ULN ) creatinine clearance equal 60mL/min , 10. adequate liver function define bilirubin less equal 1.0×ULN aspartate transferase ( AST ) alanine transferase ( ALT ) less equal 2.5 ×ULN . 1. primary malignancy 2. symptomatic central nervous system metastasis 3. pregnancy lactation 4. cardiovascular event myocardial infarction previous 6 month congestive heart failure 5. ongoing infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Esophageal Cancer</keyword>
	<keyword>nedaplatin</keyword>
	<keyword>Liposomal Paclitaxel</keyword>
</DOC>